EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Regulatory · Supplement or medicine?

Why some botanicals become supplements, while others become medicines.

The plant alone does not determine the category. U.S. law sorts a botanical by its intended use, its composition, its marketing history and the claims made for it, and the order in which a company acts can close a route.

A platform cannot bypass FDA requirements. What it can do is build the evidence and the batch-to-batch consistency that let a company choose a lawful route, and stop when none fits.

Educational schematicNot legal advice. U.S. federal law as of November 1, 2026. EUTECNIQ is in formation, with no products, studies or submissions of its own.

The same article, two orders of eventsEducational schematic of two orders of events for the same botanical article. Row A: the article is marketed as a dietary supplement or food first and a drug investigation is opened and made public later; both routes stay open, because the drug exclusion reaches only an article that was not marketed first. Row B: an IND is opened and substantial clinical investigations are made public first; a later supplement or food launch is blocked, because 21 U.S.C. 321(ff)(3)(B) excludes the article from the dietary supplement definition and 21 U.S.C. 331(ll) prohibits adding it to food, unless FDA issues a regulation after notice and comment.The same article, two orders of eventsSchematic, not to scale. U.S. law as of November 1, 2026.A · Sold as a supplement or food firstMarketed as a dietarysupplement or as a foodLater: drug IND openedand trials made publicBoth routes stay openThe exclusion reaches only anarticle that was not marketedfirstB · Drug investigation made public firstIND opened; substantialclinical investigations madepublicLater: supplement or foodlaunchSupplement and food closed21 U.S.C. 321(ff)(3)(B) and331(ll), unless FDA issues aregulationThe same article, two orders of eventsEducational schematic of two orders of events for the same botanical article. Row A: the article is marketed as a dietary supplement or food first and a drug investigation is opened and made public later; both routes stay open, because the drug exclusion reaches only an article that was not marketed first. Row B: an IND is opened and substantial clinical investigations are made public first; a later supplement or food launch is blocked, because 21 U.S.C. 321(ff)(3)(B) excludes the article from the dietary supplement definition and 21 U.S.C. 331(ll) prohibits adding it to food, unless FDA issues a regulation after notice and comment.The same article, two orders of eventsSchematic, not to scale. U.S. law as of November 1,2026.A · Sold as a supplement or food firstMarketed as a dietary supplement or as a foodLater: drug IND opened and trials made publicBoth routes stay openThe exclusion reaches only an article that was notmarketed firstB · Drug investigation made public firstIND opened; substantial clinical investigationsmade publicLater: supplement or food launchSupplement and food closed21 U.S.C. 321(ff)(3)(B) and 331(ll), unless FDAissues a regulation
Educational schematic The drug exclusion turns on order. Sources: 21 U.S.C. 321(ff)(3)(B) and 331(ll); FDA, cannabis and CBD questions Q9–Q11 (July 16, 2024). Details in section 04.

01 · The decision

Intended use sets the category

A drug is any article “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” (21 U.S.C. 321(g)(1)(B)). The same extract can therefore be a dietary ingredient, a food ingredient, a cosmetic ingredient or a drug, depending on what it is for and what is said about it.

Schematic, Intended use sets the category: One botanical extract Intended use and claims set the route Dietary supplement Notification for a new dietary ingredient; Part 111 manufacturing No FDA approval Conventional food GRAS for the intended use, or a food additive petition Approval only by petition Cosmetic Safety substantiation; registration and listing where they apply No FDA approval Botanical drug IND, consistency of a mixture, then NDA FDA approval required Isolated active ingredient A conventional new drug FDA approval required Only the drug routes and a food or color additive petition need FDA approval before marketing. Educational schematic, simplified from 21 U.S.C. 321 and the regulations cited on this page. Legal conclusions belong with counsel.
Schematic Educational schematic drawn by EUTECNIQ from the statutes and regulations cited on this page. Legal conclusions belong with counsel.
01

Use and claims are read from everything said

FDA infers intended use from claims in labeling, advertising and on the internet, from consumer perception, and from ingredients with a well-known therapeutic use. The FTC holds a marketer “equally responsible for the accuracy of claims suggested or reasonably implied.”

02

Composition and history set the file

A dietary ingredient sold in the United States before October 15, 1994 is not “new.” A newer one needs a notification unless it was in the food supply, chemically unaltered. An article that was a drug first cannot become a supplement or a food ingredient.

03

Evidence decides what can be said

A supplement may describe effects on normal structure or function with a disclaimer. Disease-risk claims need an FDA regulation or a letter of enforcement discretion. A claim to treat disease needs an approved drug application.

Sources: 21 U.S.C. 321(g)(1), 350b(d) and 350b(a); FDA, “Is It a Cosmetic, a Drug, or Both?” (September 11, 2024); FTC, Health Products Compliance Guidance (December 2022), Section III.A.1; 21 CFR 101.14 and 101.93. Full list under References.

Next: answer the nine inputs for one ingredient.

02 · Decision tree

Nine inputs place a botanical on one route, through eight gates in a fixed order

The gates follow the statute: a disease claim is checked before anything else, and the drug-first question before any food or supplement route. Choose an answer for each input; the tree marks the gate where the path leaves the main line and lists what your answers add.

Eight gates, in statutory orderEducational schematic. A botanical article passes eight gates in order; at each gate one answer leaves the main line for an outcome. 1, disease use or disease claim: yes leads to a drug, IND then NDA or BLA. 2, applied to the body for appearance: yes leads to a cosmetic, with safety substantiation and MoCRA listing, and drug rules if it makes drug claims. 3, intended for ingestion: no means it is not a food or supplement; an article other than food intended to affect the structure or function of the body is a drug. 4, approved or publicly investigated as a drug first: yes means drug only, with the supplement and food channels closed. 5, sold as a conventional food: yes leads to a GRAS conclusion for the intended use or a food additive petition. 6, a dietary ingredient sold before October 15, 1994 and unchanged: yes means a supplement whose ingredient is not new, with no notification. 7, only ingredients present in the food supply and not chemically altered: yes means the new dietary ingredient is exempt from notification under section 413(a)(1). 8, every other dietary supplement ingredient: notify FDA at least 75 days before sale.01Disease use or adisease claim?02Applied to the bodyfor appearance?03Intended foringestion?04Approved, orpubliclyinvestigated, as adrug first?05Sold as aconventional food?06Dietary ingredientsold before Oct 15,1994, unchanged?07Only in the foodsupply, notchemically altered?08Every other dietarysupplementingredientYesNoDrugIND, then NDA or BLAYesNoCosmeticsafety substantiation;MoCRA listing; drugrules if it makes drugclaimsNoYesNot a food orsupplementif intended to affectthe body's structure orfunction, it is a drugYesNoDrug onlysupplement and foodchannels closedYesNoConventional foodGRAS for theintended use, or afood additive petitionYesNoSupplement, not anNDIno notification; Part111, labeling and claimrulesYesNoSupplement, NDIexempt§ 413(a)(1): nonotificationSupplement with anNDInotify FDA at least 75days before saleEight gates, in statutory orderEducational schematic. A botanical article passes eight gates in order; at each gate one answer leaves the main line for an outcome. 1, disease use or disease claim: yes leads to a drug, IND then NDA or BLA. 2, applied to the body for appearance: yes leads to a cosmetic, with safety substantiation and MoCRA listing, and drug rules if it makes drug claims. 3, intended for ingestion: no means it is not a food or supplement; an article other than food intended to affect the structure or function of the body is a drug. 4, approved or publicly investigated as a drug first: yes means drug only, with the supplement and food channels closed. 5, sold as a conventional food: yes leads to a GRAS conclusion for the intended use or a food additive petition. 6, a dietary ingredient sold before October 15, 1994 and unchanged: yes means a supplement whose ingredient is not new, with no notification. 7, only ingredients present in the food supply and not chemically altered: yes means the new dietary ingredient is exempt from notification under section 413(a)(1). 8, every other dietary supplement ingredient: notify FDA at least 75 days before sale.01Disease use or a disease claim?Yes: DrugIND, then NDA or BLA02Applied to the body for appearance?Yes: Cosmeticsafety substantiation; MoCRA listing; drug rulesif it makes drug claims03Intended for ingestion?No: Not a food or supplementif intended to affect the body's structure orfunction, it is a drug04Approved, or publicly investigated, as a drugfirst?Yes: Drug onlysupplement and food channels closed05Sold as a conventional food?Yes: Conventional foodGRAS for the intended use, or a food additivepetition06Dietary ingredient sold before Oct 15, 1994,unchanged?Yes: Supplement, not an NDIno notification; Part 111, labeling and claim rules07Only in the food supply, not chemicallyaltered?Yes: Supplement, NDI exempt§ 413(a)(1): no notification08Every other dietary supplement ingredientSupplement with an NDInotify FDA at least 75 days before sale
Educational schematic Eight gates simplified from 21 U.S.C. 321(f), (g)(1), (i) and (ff), 331(ll) and 350b, 21 CFR 101.93(f) and 190.6. Drug outcomes then split by composition: a botanical mixture follows FDA's botanical drug guidance; a highly purified constituent does not. OTC monographs, color additives and state law are omitted.
Text version: the eight gates, the nine results and every note the tree can add

The eight gates, in order

Each gate is checked only if the article passed every gate before it.
GateQuestionAnswer that leaves the lineRule
01Is there a disease use, or a claim to diagnose, cure, mitigate, treat or prevent a disease?Yes: a drug21 U.S.C. 321(g)(1)(B); 21 CFR 101.93(f)
02Is it applied to the body to cleanse, beautify, promote attractiveness or alter the appearance?Yes: a cosmetic, and also a drug if it makes drug claims21 U.S.C. 321(i); FDA, “Is It a Cosmetic, a Drug, or Both?”
03Is it intended for ingestion?No: not a food or supplement; an article other than food intended to affect the body's structure or function is a drug21 U.S.C. 321(f), (ff)(2) and (g)(1)(C)
04Was it approved as a drug, or authorized for investigation with substantial public clinical investigations, before it was marketed as a supplement or food?Yes: drug only; the supplement and food channels are closed21 U.S.C. 321(ff)(3)(B) and 331(ll)
05Is it sold as a conventional food or beverage?Yes: a GRAS conclusion for the intended use, or a food additive petition21 U.S.C. 321(f) and (s); 21 CFR 170.30 and 171.1
06Was the dietary ingredient marketed in the United States before October 15, 1994, documented and unchanged?Yes: not a new dietary ingredient; no notification21 U.S.C. 350b(d)
07Does the supplement contain only dietary ingredients present in the food supply as an article used for food, in a form not chemically altered?Yes: new dietary ingredient, exempt from notification21 U.S.C. 350b(a)(1)
08Every other dietary supplement ingredientNotify FDA at least 75 days before marketing21 U.S.C. 350b(a)(2); 21 CFR 190.6

The nine results

  • Drug The intended use or the claim makes the article a drug. It may not be marketed without an approved application (21 U.S.C. 355(a)); clinical investigation runs under an IND. Next: decide whether the program stays botanical or isolates a constituent, then plan the IND package with counsel and a qualified clinical partner.
  • Cosmetic A cosmetic needs no FDA approval, except for color additives. The responsible person keeps safety substantiation and, unless an exemption applies, registers the facility and lists the product under MoCRA. Next: write the claims list and check each one against FDA's cosmetic-or-drug examples before any safety work is scoped.
  • Not a food or supplement A product not intended for ingestion cannot be a food or a dietary supplement. If it is intended to affect the structure or function of the body, it meets the drug definition. Next: confirm the route and the intended effect with counsel before formulation work begins.
  • Drug only The article was a drug first. It is excluded from the dietary supplement definition, and adding it to food is a prohibited act, unless FDA issues a regulation after notice and comment. Next: document the dates with counsel; if the exclusion holds, the only U.S. route is drug development.
  • Conventional food An added botanical ingredient needs a basis for GRAS status for its intended conditions of use, or a food additive regulation issued on petition. Next: fix the foods, use levels and estimated intake, because GRAS status attaches to those conditions of use.
  • Supplement, not an NDI An ingredient marketed in the United States before October 15, 1994 is not a new dietary ingredient, so no premarket notification is required. Part 111, labeling and claim rules still apply. Next: assemble dated evidence of pre-1994 marketing and compare the historical article with today's material.
  • Supplement, NDI exempt A new dietary ingredient needs no notification when the supplement contains only ingredients present in the food supply as an article used for food, in a form not chemically altered (§ 413(a)(1)). Next: document the food use and show the supplement's form is the same, chemically unaltered.
  • Supplement with an NDI The manufacturer or distributor files the basis for concluding the supplement “will reasonably be expected to be safe” at least 75 days before marketing. FDA does not approve the notification. Next: fix identity, intake and the safety gap, then commission only the studies that close it.
  • Isolated-constituent drug FDA's botanical drug pages exclude highly purified substances, whether naturally derived or chemically modified. A purified constituent is developed as a conventional new drug, with a defined drug substance. Next: check the drug-first status and the patent position of the constituent before any public study.

Every note the tree can add, by input

  • Use: appearance, taken by mouth The cosmetic definition covers articles applied to the body for appearance (21 U.S.C. 321(i)). A product swallowed for an effect on the skin is treated here as a supplement, so its statements follow the supplement claim rules. Counsel decides close cases.
  • Claim: treats or prevents a disease The claim alone makes it a drug: with a disease claim, a product marketed as a supplement “will be subject to regulation as a drug unless the claim is an authorized health claim for which the product qualifies” (21 CFR 101.93(f)).
  • Cosmetic with a structure/function claim FDA lists claims such as regenerating cells or restoring hair growth as drug claims. “A product can be a drug, a cosmetic or both,” and then drug requirements, including drug GMP, apply. MoCRA's registration, listing and safety-substantiation provisions do not apply to a product subject to the drug chapter (21 U.S.C. 364i).
  • Cosmetic with a health claim Health claims and qualified health claims are claims for foods and dietary supplements (21 CFR 101.14; FDA label claims page). They give a cosmetic no route, and a claim about disease makes a product a drug (21 U.S.C. 321(g)(1)(B)).
  • Route: not swallowed A dietary supplement must be intended for ingestion (21 U.S.C. 321(ff)(2)), and food is what people eat or drink (321(f)). An inhaled or injected botanical, or a topical one that is not for appearance, falls outside both; if it is intended to affect the structure or function of the body it meets the drug definition (321(g)(1)(C)).
  • History: drug first The supplement definition excludes an article approved as a new drug, or authorized for investigation with substantial public clinical investigations, that was not marketed as a supplement or food before (21 U.S.C. 321(ff)(3)(B)); section 331(ll) bars adding such a drug to food. FDA applied both to CBD, the active ingredient of Epidiolex, and states that no regulation lifting the exclusion “has been issued for any substance.”
  • History: not known Establish the dates before going further. The tree has assumed no drug came first, and without documented pre-1994 sales it routes to notification. FDA may not disclose when an article was authorized for investigation; in the NMN matter it wrote, “we cannot specify the date of authorization.”
  • History: before 1994, process changed An ingredient marketed before October 15, 1994 is not “new” (21 U.S.C. 350b(d)), but when a manufacturing change creates a new dietary ingredient is addressed only in FDA's 2016 draft guidance (Section IV.A). With a changed process the tree does not treat the ingredient as old.
  • History: in food; process changed The § 413(a)(1) exception needs a form in which the food “has not been chemically altered.” FDA's reading of that phrase is only in the 2016 draft guidance (Section IV.B). A changed process can lose the exception, so the tree routes to notification.
  • Extract relying on the food-supply exception Whether an extract is “chemically altered” is addressed only in FDA's 2016 draft guidance (Section IV.B). Counsel would confirm before a company relies on the exception.
  • Composition: single constituent as a supplement A “constituent” or “extract” of a botanical is a dietary ingredient category (21 U.S.C. 321(ff)(1)(F)). FDA's views on synthetic copies are in draft guidance (2016, Section IV.D). FDA's two most-cited drug-exclusion matters, CBD and NMN, both concern single substances.
  • Change: nanoscale form For an NDI, FDA states that data on the conventional form alone “are unlikely to address safety concerns specific to the nanomaterial- or nanotechnology-modified version” (October 2026 guidance, Section VIII.2), and FDA's 2014 guidance asks whether any FDA-regulated product involves nanotechnology. A smaller droplet is a delivery property; it is not, by itself, evidence of greater bioavailability.
  • Change: synthetic or fermentation-derived A synthetic or fermentation-derived version is a different article from the plant material. FDA's views on synthetic constituents are in draft guidance (2016, Section IV.D), and FDA's botanical drug guidance excludes fermentation products made to yield a single molecular entity (Section II).
  • Botanical drug: consistency FDA judges therapeutic consistency from the totality of the evidence: raw-material control, chemistry and manufacturing control, a biological assay and clinical data (2016 guidance, Sections III.B and VII.F). Raw-material and process changes have to preserve it.
  • Dose: above history History of use covers only the intake and duration it documents. FDA's NDI guidance compares the estimated daily intake (EDI) with an acceptable daily intake (ADI = NOAEL ÷ safety factor; EDI/ADI ≤ 1 supports safety, Section IX), and the botanical drug guidance notes more testing may be needed when exposure exceeds prior human use (Section V.C). EFSA found 800 mg EGCG a day or more, taken as a food supplement, significantly raised serum transaminases.
  • Dose: not established An NDI notification states the level of the NDI and the conditions of use (21 CFR 190.6(b)(3)), and GRAS status attaches to intended conditions of use. Intake is the first number to fix.
  • Population: children or adolescents The safety case has to cover the intended users at their intake. New York bars selling weight-loss or muscle-building supplements to anyone under eighteen (General Business Law § 391-oo).
  • Population: pregnancy or breastfeeding FDA's Standard Safety Testing Table (Appendix A of the October 2026 NDI guidance) lists studies by level of concern, and firms are “not required to complete and submit all the studies listed in a given row.” Which studies this population needs is a judgment for qualified toxicologists.
  • Population: people with a disease FDA treats a statement as a disease claim if it suggests the product substitutes for, or augments, a therapy for disease (21 CFR 101.93(g)(2)(vi)–(vii)). Interactions matter: an extract supplying 41 mg hyperforin a day cut oral midazolam exposure by 79.4% in one study group (Mueller et al. 2006). A study of a supplement's ability to treat or prevent disease needs an IND.
  • Claim: structure/function, supplement Notify FDA no later than 30 days after first marketing. The label carries “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” The firm holds substantiation that the statement is truthful and not misleading (21 CFR 101.93(a), (c); 21 U.S.C. 343(r)(6)).
  • Claim: structure/function, food Food structure/function claims “focus on effects derived from nutritive value.” FDA does not require notification, and disclaimers are not required (FDA, Label Claims for Conventional Foods and Dietary Supplements).
  • Claim: authorized health claim An authorized health claim exists only where an FDA regulation authorizes the substance–disease relationship on “significant scientific agreement” (21 CFR 101.14(c)), and the product meets its conditions; for psyllium husk and coronary heart disease, 21 CFR 101.81 requires at least 1.7 g of soluble fiber per serving. A new relationship needs a petition.
  • Claim: qualified health claim A qualified claim rests on evidence below significant scientific agreement. On petition, if the evidence is credible, FDA issues a letter stating when it intends to exercise enforcement discretion; the claim then uses the letter's qualifying language and is available to any food or supplement meeting its conditions.

Evidence checks

  • Drug, evidence below disease-endpoint trials Approval rests on adequate and well-controlled investigations (21 CFR 314.126). The next step is an IND with protocols, chemistry, manufacturing and controls, and pharmacology and toxicology information (21 CFR 312.23(a)).
  • Drug, disease-endpoint trials These are the kind of studies an NDA relies on; FDA decides whether they are adequate and well controlled, and the application must permit a “knowledgeable judgment” (21 CFR 314.50(d)).
  • Health-related claim, evidence below randomized trials FTC: as a general matter, “substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing,” relevant “to their specific product and to the specific advertised benefit.” Traditional use, animal or cell studies alone do not meet that bar.
  • Health-related claim, randomized trials Product-specific randomized trials are what FTC says experts generally require; the fit between the tested product, dose and the advertised benefit still has to be shown.
  • NDI, traditional use only If history of use alone is relied on, FDA “generally recommends 25 years of widespread use to be the minimum” (a recommendation). Otherwise the notification draws on safety studies listed in FDA's Appendix A table, not all of which are required.
  • NDI, safety data available Your data feed the safety narrative and safety calculations of FDA's October 2026 guidance. Whether they suffice is the notifier's documented conclusion, filed 75 days ahead; FDA's silence is not a finding of safety (21 CFR 190.6(f)).
  • No notification required The supplement still must not be adulterated. FDA's draft guidance takes the view that the “reasonably expected to be safe” standard applies even when no notification is required (2016 draft; a draft position).
  • Food ingredient GRAS through scientific procedures “shall require the same quantity and quality of scientific evidence as is required to obtain approval of a food additive” (21 CFR 170.30(b)), and must be generally recognized by qualified experts.
  • Cosmetic Safety substantiation is evidence qualified experts consider sufficient for “a reasonable certainty that a cosmetic product is safe” (21 U.S.C. 364d). FDA: “Neither the law nor FDA regulations require specific tests to demonstrate the safety of individual products or ingredients.”

Sources for every note are listed under References; route requirements are in section 03.

Next: read what the route you reached requires.

03 · The routes

Five routes, five different files. Only the drug routes and a food or color additive petition need FDA approval before marketing

FDA approves drugs, food additives and color additives before marketing. It does not approve dietary supplements, new dietary ingredient notifications or cosmetics. Open a route to see what it requires and what it does not mean.

Published evidenceStatutes, regulations and agency documents, status checked November 1, 2026.

Food · dietary supplementDietary supplement: ODI, NDI and the notification

What it is

  • A product “intended to supplement the diet” containing a dietary ingredient, including “an herb or other botanical” or its “concentrate, metabolite, constituent, extract, or combination.” It is intended for ingestion, “not represented for use as a conventional food,” and “labeled as a dietary supplement” (21 U.S.C. 321(ff)).
  • Old or new. A new dietary ingredient (NDI) is one “not marketed in the United States before October 15, 1994” (§ 413(d)). An ingredient sold before then, often called an old dietary ingredient (ODI), needs no notification; the marketer should be able to document that sale.
  • Notification and its exception. An NDI needs a notification (NDIN) filed at least 75 days before interstate marketing, unless the supplement “contains only dietary ingredients which have been present in the food supply as an article used for food in a form in which the food has not been chemically altered” (§ 413(a)(1)–(2); 21 CFR 190.6).

What the file must show

  • Identity and safety. The notification names the NDI, for a botanical by its Latin binomial name including the author, states its level and conditions of use, and gives the history of use or other evidence of safety (21 CFR 190.6(b)). FDA's October 2026 final guidance covers identity, history of use, a safety narrative and safety calculations.
  • Manufacturing. Part 111 applies to anyone who manufactures, packages, labels or holds a dietary supplement, including identity testing of each dietary ingredient (21 CFR 111.1, 111.75). An ingredient-only operation is generally under Part 117 instead.
  • Labeling and claims. A Supplement Facts panel, with botanicals listed by the part of the plant (21 CFR 101.36). Structure/function statements need a 30-day notice, the disclaimer and substantiation (21 CFR 101.93). Serious adverse events are reported to FDA within 15 business days (21 U.S.C. 379aa-1).

What it is not

An NDIN acknowledgment is not FDA approval, FDA silence is not a finding of safety, and Part 111 compliance is not drug GMP.

“FDA does not approve NDI notifications; no FDA approval is required or issued at any point in this process” (FDA, October 2026). When a notification is required, including what “chemically altered” means, is still only in FDA's 2016 draft guidance.

Sources: 21 U.S.C. 321(ff), 350b, 343(r)(6), 379aa-1; 21 CFR 190.6, 111, 101.36, 101.93; FDA NDI identity and safety guidance (October 2026); FDA NDI procedures guidance (March 2024); FDA revised draft guidance (2016, October 2026 revision). NDIN guide →

Food · conventional food ingredientConventional food: GRAS for the intended use, or a food additive petition

What it is

  • A substance added to food is a food additive unless it is generally recognized as safe for its intended use (21 U.S.C. 321(s)). In FDA's words, “the conditions of intended use of a substance, rather than the substance itself, are eligible for GRAS status.”
  • GRAS through scientific procedures “shall require the same quantity and quality of scientific evidence as is required to obtain approval of a food additive,” and recognition “may be based only on the views of experts qualified by scientific training and experience” (21 CFR 170.30). A substance not in common food use before January 1, 1958 can be GRAS only through scientific procedures.
  • Otherwise, a food additive petition with identity, each proposed use and “full reports of investigations made with respect to the safety” (21 CFR 171.1); FDA issues a regulation or denies it. “Safe” means “a reasonable certainty in the minds of competent scientists that the substance is not harmful under the conditions of its intended use” (21 CFR 170.3(i)).

Food-safety obligations and claims

  • Food safety. Part 117 CGMP and hazard analysis and risk-based preventive controls apply to food facilities; importers run foreign supplier verification programs (21 CFR Part 1, Subpart L).
  • GRAS notices. Notifying FDA is voluntary today; FDA responds within 180 days of filing, extendable by 90. FDA's August 11, 2026 proposal would make GRAS notices mandatory; comments are due December 9, 2026.
  • Claims. Food structure/function claims “focus on effects derived from nutritive value,” with no notification and no disclaimer. Authorized and qualified health claims and nutrient content claims are available to foods.

What it is not

A GRAS conclusion does not cover every use or every country, and a “no questions” letter is not FDA approval.

GRAS is not the route for a supplement ingredient: ingredients in or intended for dietary supplements are outside the food additive definition, so FDA's 2026 proposal states they “are not eligible for classification as GRAS.”

Sources: 21 U.S.C. 321(f), (s); 21 CFR 170.3, 170.30, Part 170 Subpart E, 171.1, Part 117, Part 1 Subpart L; 91 FR 51834 (August 11, 2026); FDA, Label Claims for Conventional Foods and Dietary Supplements (March 28, 2024). GRAS guide →

Cosmetic · MoCRACosmetic: safety substantiation, registration and listing where they apply

What it is

  • Articles “intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body” for “cleansing, beautifying, promoting attractiveness, or altering the appearance” (21 U.S.C. 321(i)).
  • The responsible person must ensure, and keep records supporting, “adequate substantiation of safety”: evidence qualified experts consider sufficient for “a reasonable certainty that a cosmetic product is safe” (21 U.S.C. 364d). “Neither the law nor FDA regulations require specific tests.”

MoCRA, where applicable

  • Facilities register and renew every two years; each product is listed with its ingredients and the listing updated annually (21 U.S.C. 364c). Serious adverse events go to FDA within 15 business days (364a).
  • Firms with average U.S. cosmetic sales below $1,000,000 a year over the previous three years, adjusted for inflation, are not subject to the GMP and registration-and-listing sections (364h). Products also subject to the drug chapter are exempt from several MoCRA provisions and follow drug rules (364i).
  • FDA has proposed no cosmetic GMP rule, although the statutory deadlines of December 29, 2024 and December 29, 2025 have passed.

When it becomes a drug

Intended use decides. FDA lists claims to restore hair growth, reduce cellulite, increase or decrease melanin production or regenerate cells as drug claims. “A product can be a drug, a cosmetic or both”; a cosmetic that is also a drug must meet drug requirements, including drug GMP.

Registration and listing are not FDA approval.

Sources: 21 U.S.C. 321(i), 364a, 364c, 364d, 364h, 364i; FDA, MoCRA page (August 10, 2026); FDA, “FDA Authority Over Cosmetics” (November 18, 2025); FDA, “Is It a Cosmetic, a Drug, or Both?” (September 11, 2024). Cosmetics guide →

Drug · botanical drugBotanical drug: IND, consistency of a mixture, then NDA

What it is

  • FDA: “Botanical drug products, or BDPs, refer to drug products that include or may be derived from plant materials,” algae and macroscopic fungi. A botanical “may be classified as a food (including a dietary supplement), drug,” depending “in large part on its intended use” (2016 guidance, Section III).
  • A sponsor “shall submit an IND” before a clinical investigation (21 CFR 312.20); it holds protocols, chemistry, manufacturing and controls (CMC), pharmacology and toxicology, and previous human experience. It takes effect 30 days after FDA receives it unless FDA imposes a clinical hold (312.40(b)).
  • A study of a supplement's effect on structure or function needs no IND; one of its ability to treat or prevent disease does (FDA, 2013).

Consistency of a mixture

  • “Therapeutic consistency can be supported by a ‘totality of the evidence’ approach” (Section III.B): raw-material control, CMC control, a biological assay and clinical data, assessed together (VII.F).
  • FDA recommends raw material “from three or more representative cultivation sites or farms” for late-phase trials (VI.C.1), a biological assay before Phase 3 (V.B.2), and “randomization of subjects to different batches in each site is highly recommended” (VI.F.1).
  • For a product lawfully marketed as a supplement with no known safety issues, early trials may need less CMC detail and may proceed “without further nonclinical pharmacological/toxicological testing” (V.B, V.C).

Approval

A new drug may not be marketed without an approved application (21 U.S.C. 355(a)); approval rests on adequate and well-controlled studies (21 CFR 314.126), and drug products are made under Parts 210 and 211. FDA lists four botanical products approved as prescription drugs: sinecatechins (Veregen, NDA, 2006), crofelemer (Fulyzaq, also Mytesi, NDA, 2012), anacaulase-bcdb (NexoBrid, BLA, 2022) and birch triterpenes (Filsuvez, NDA, 2023).

Sources: FDA CDER, What is a Botanical Drug? (September 3, 2026); FDA Botanical Drug Development guidance (December 2016); FDA IND guidance (September 2013); 21 CFR 312.20, 312.23, 312.40, 314.50, 314.126, Parts 210–211; 21 U.S.C. 355(a); approval years from Park et al., Ther Innov Regul Sci 2025. Food–drug gap guide →

Drug · isolated constituentIsolated active ingredient: a conventional new drug

What it is

  • FDA's botanical drug pages exclude “highly purified substances, either derived from naturally occurring sources or chemically modified,” and fermentation products made to yield a single molecular entity. A purified constituent developed for disease is a conventional new drug with one defined drug substance.
  • It follows the IND and NDA rules above; the active pharmaceutical ingredient is made under drug GMP (ICH Q7 for active ingredients; Parts 210 and 211 for the drug product). A drug that fails GMP is adulterated (21 U.S.C. 351(a)(2)(B)).

As a supplement ingredient

  • A botanical “constituent” is a dietary ingredient category (21 U.S.C. 321(ff)(1)(F)), so a purified constituent can be a supplement ingredient, usually an NDI, unless the drug exclusion applies.
  • FDA applied the exclusion to CBD and THC, active ingredients of approved drugs. For NMN it first excluded the substance (October 11, 2022) and then concluded, on evidence of supplement sales “as early as 2017,” that NMN “is not excluded” (September 2025).

What it is not

A constituent isolated from a plant is not a botanical drug, and manufacture under Part 111 is not API manufacture under drug GMP.

Sources: FDA CDER, What is a Botanical Drug?; FDA Botanical Drug Development guidance (2016), Section II; ICH Q7; 21 CFR Parts 210–211; 21 U.S.C. 321(ff)(1)(F), 351; FDA cannabis and CBD page (July 16, 2024); FDA response to citizen petition FDA-2023-P-0872 (September 2025). Legal status guide →

Next: see why the routes cannot be taken in any order.

04 · Order matters

A public drug program can close the supplement and food routes for everyone

The supplement definition excludes an article that was a drug first, and adding such an article to food is a prohibited act. The reverse does not hold: a botanical already sold lawfully as a supplement can still be developed as a drug, sometimes with less early work.

“[The term dietary supplement] does … (B) not include— (i) an article that is approved as a new drug under section 355 of this title, certified as an antibiotic under section 357 of this title, or licensed as a biologic under section 262 of title 42, or (ii) an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, which was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food unless the Secretary, in the Secretary's discretion, has issued a regulation, after notice and comment, finding that the article would be lawful under this chapter.”

Statute FD&C Act § 201(ff)(3)(B); 21 U.S.C. 321(ff)(3)(B). Section 301(ll), 21 U.S.C. 331(ll), applies the same test to food.

Why the routes cannot be taken in any order

  1. Drug first closes two doors. Once an article is approved, or publicly under substantial clinical investigation, before any supplement or food sale, it cannot later be sold as either, unless FDA issues a regulation. FDA states that no such regulation “has been issued for any substance.”
  2. Supplement first keeps both open. The exclusion does not reach an article marketed first. FDA's botanical drug guidance lets a lawfully marketed supplement with no known safety issues start trials with less CMC detail and without further nonclinical testing.
  3. A claim cannot be added later. A disease claim on a supplement makes it a drug unless it is an authorized health claim for which the product qualifies (21 CFR 101.93(f)).
  4. A changed process can reopen the question. When a manufacturing change creates a new dietary ingredient, or ends the food-supply exception, is addressed in FDA's 2016 draft guidance (Sections IV.A, IV.B).
  5. The dates may be invisible. FDA may not disclose when an article was authorized for investigation, and its reading can change: for NMN it reversed its 2022 exclusion in September 2025.

Sources: 21 U.S.C. 321(ff)(3)(B), 331(ll); FDA, cannabis and CBD questions Q9–Q11 (July 16, 2024); FDA response to citizen petition FDA-2023-P-0872 (September 2025); FDA Botanical Drug Development guidance (2016), Sections V.B and V.C; 21 CFR 101.93(f); FDA 2016 revised draft guidance (October 2026 revision).

Next: test how wording and context change a claim.

05 · Claims explorer

Wording and context show intended use, and intended use decides what a claim is

Thirteen hypothetical statements, each with the rule that classifies it. FDA judges a disease claim “in context,” including the product name, pictures and cited publications; the FTC judges the “net impression” of the whole advertisement.

All thirteen examples as a table
Hypothetical statements written for teaching. Product names and wording are invented; real cases depend on the full label and context.
StatementContextLikely categoryWhat it requiresRule
“Supports healthy digestion.”Botanical supplement labelStructure/function statementNotice to FDA no later than 30 days after first marketing, the disclaimer on each panel bearing the claim, and substantiation that it is truthful and not misleading21 U.S.C. 343(r)(6); 21 CFR 101.93(a), (c)
“The fiber in this cereal supports regularity.”Conventional food with psyllium fiberFood structure/function claimAn effect derived from nutritive value; no FDA notification and no disclaimerFDA, Label Claims for Conventional Foods and Dietary Supplements
“Soluble fiber from psyllium husk may reduce the risk of coronary heart disease.”Food or supplement worded and qualified as the regulation requiresAuthorized health claimThe conditions of 21 CFR 101.81, including at least 1.7 g of soluble fiber from psyllium seed husk per serving21 CFR 101.14(c), 101.81
A cranberry product's claim on reduced risk of recurrent urinary tract infection in healthy womenUsing the qualifying language of FDA's letter of July 21, 2020Qualified health claimThe letter's exact qualifying language and conditions; FDA exercises enforcement discretion, it does not authorize the claim by regulationFDA, qualified health claims letters; FDA label claims page
“Relieves arthritis pain.”Botanical supplement labelDisease claim: the product is a drugAn approved drug application, after clinical investigation under an IND21 CFR 101.93(f), (g)(2)(i)–(ii); 21 U.S.C. 321(g)(1)(B)
“Supports joint comfort.”The brand name is built on the word “arthritis”Implied disease claim through the product nameA different name, or drug approval; the statement alone would be structure/function21 CFR 101.93(g)(2)(iv)(A)
“Supports easy breathing.”Shown beside a picture of an asthma inhalerLikely implied disease claim through a pictureRemoving the image, or drug approval; FDA judges such cases in context21 CFR 101.93(g)(2)(iv)(E); FTC net impression
“Take with your blood-pressure medication for better results.”Supplement websiteDisease claim: augments a drug therapyDrug approval; the statement also invites an interaction question21 CFR 101.93(g)(2)(vii); intended use read from websites (FDA)
“Clinically studied” with a link to a trial titled “… in patients with type 2 diabetes”Product page citing the publication prominentlyImplied disease claim through a citationRemoving the disease-use citation from labeling, or drug approval21 CFR 101.93(g)(2)(iv)(C)
“Clinically proven to improve focus.”Evidence: one cell-culture study of a related extractStructure/function in form; unsubstantiated under FTC lawGenerally, randomized controlled human trials relevant to the specific product and the specific advertised benefit, plus the FDA notice and disclaimerFTC Health Products Compliance Guidance, Sections III.B.2, III.B.5; 21 CFR 101.93
“Traditionally used in Ayurveda to support digestion.”U.S. supplement labelHealth-related claim needing the usual substantiationCompetent and reliable scientific evidence, as for any other claim; the FDA notice and disclaimerFTC Health Products Compliance Guidance; 21 CFR 101.93
“Smooths the look of fine lines.”Topical creamCosmetic claim about appearanceSafety substantiation records; facility registration and product listing unless exempt21 U.S.C. 321(i), 364c, 364d
“Boosts collagen to regenerate skin cells.”Topical creamDrug claim: affects the structure or function of the bodyDrug requirements, including drug GMP; the product can be a cosmetic and a drugFDA, “Is It a Cosmetic, a Drug, or Both?”; 21 U.S.C. 321(g)(1)(C)

A notified structure/function claim is not an FDA-reviewed claim, traditional use is not substantiation, and a qualified health claim is not an authorized health claim.

Sources: 21 CFR 101.14, 101.81, 101.93 (eCFR, up to date as of October 23, 2026); FDA, Label Claims for Conventional Foods and Dietary Supplements (March 28, 2024); FDA, qualified health claims letters; FDA, “Is It a Cosmetic, a Drug, or Both?” (September 11, 2024); FTC, Health Products Compliance Guidance (December 2022), which “doesn't have the force or effect of law.” Not legal advice.

Next: see how EUTECNIQ proposes to build the evidence for a route.

06 · What EUTECNIQ would deliver

The proposed platform would build the evidence a company needs to choose a lawful route

The route is screened at intake and re-assessed whenever the material, process, formulation or intended use changes. Each item below is a proposal; EUTECNIQ has not built or performed any of it.

01

Route screen at intake

The nine inputs answered with documents and repeated at each material or process change. Legal conclusions go to counsel.

Proposed capability

02

Marketing-history file

Dated evidence of first U.S. sale, a search of public trial registries and the drug-first check, assembled before any study becomes public.

Proposed capability

03

One identity file, two uses

Latin binomial with author, plant part, chemical fingerprint and batch ranges. The same file serves an NDI identity section and a botanical drug's raw-material and CMC controls.

Proposed capability

04

Exposure and safety case

Intake fixed first, then the estimated daily intake against an acceptable daily intake, with studies run by qualified laboratories only where a gap exists.

Proposed capability

05

Claims-to-evidence map

Each intended statement tied to the evidence it needs and reviewed for implied disease meaning in name, images and citations before launch.

Proposed capability

06

A stop decision

When no route fits the claim the evidence can support, the recommendation is to stop or to change the intended use, not to reword the label.

Proposed capability

08 · References

Sources

Statutes from Cornell LII; regulations from the eCFR (an unofficial compilation, up to date as of October 21–23, 2026); agency pages with their “content current as of” dates. Read October 22 to November 1, 2026.

supplement or medicine, statutes and regulations

  1. 21 U.S.C. 321 (FD&C Act § 201), definitions: (f) food, (g)(1) drug, (i) cosmetic, (s) food additive, (ff) dietary supplement, including the drug exclusion of (ff)(3)(B). Cornell LII, read October 28, 2026. law.cornell.edu/uscode/text/21/321
  2. 21 U.S.C. 331(ll) (FD&C Act § 301(ll)), prohibited act: introducing into interstate commerce a food to which an approved drug, a licensed biologic, or a drug or biologic under publicly known substantial clinical investigation has been added, with four exceptions. Cornell LII, read November 1, 2026. law.cornell.edu/uscode/text/21/331
  3. 21 U.S.C. 343(r)(6) (FD&C Act § 403(r)(6)), structure/function statements on dietary supplements: substantiation, disclaimer and 30-day notice. Cornell LII. law.cornell.edu/uscode/text/21/343
  4. 21 U.S.C. 350b (FD&C Act § 413), new dietary ingredients: (a)(1) food-supply exception, (a)(2) notification at least 75 days before marketing, (d) definition. Cornell LII. law.cornell.edu/uscode/text/21/350b
  5. 21 U.S.C. 355 (FD&C Act § 505), new drugs, subsection (a). Cornell LII. law.cornell.edu/uscode/text/21/355
  6. 21 U.S.C. 351 (FD&C Act § 501), adulterated drugs, (a)(2)(B) current good manufacturing practice. Cornell LII. law.cornell.edu/uscode/text/21/351
  7. 21 U.S.C. 379aa-1, serious adverse event reporting for dietary supplements. Cornell LII. law.cornell.edu/uscode/text/21/379aa-1
  8. 21 U.S.C. 364a (FD&C Act § 605), serious adverse event reporting for cosmetics. Cornell LII. law.cornell.edu/uscode/text/21/364a
  9. 21 U.S.C. 364c (FD&C Act § 607), cosmetic facility registration and product listing. Cornell LII. law.cornell.edu/uscode/text/21/364c
  10. 21 U.S.C. 364d (FD&C Act § 608), safety substantiation, including the definition of adequate substantiation of safety. Cornell LII. law.cornell.edu/uscode/text/21/364d
  11. 21 U.S.C. 364h (FD&C Act § 612), small businesses. Cornell LII. law.cornell.edu/uscode/text/21/364h
  12. 21 U.S.C. 364i (FD&C Act § 613), exemption for certain products and facilities, including products also subject to the drug and device chapter. Cornell LII. law.cornell.edu/uscode/text/21/364i
  13. 21 CFR 101.14, health claims: general requirements, (c) significant scientific agreement. eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-A/section-101.14
  14. 21 CFR 101.36, nutrition labeling of dietary supplements (the Supplement Facts panel; botanicals listed with the part of the plant). eCFR, up to date as of October 23, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-C/section-101.36
  15. 21 CFR 101.81, health claims: soluble fiber from certain foods and risk of coronary heart disease (psyllium husk). eCFR, read October 28, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-E/section-101.81
  16. 21 CFR 101.93, certain types of statements for dietary supplements: (a) notification, (c) disclaimer, (f) disease claims, (g) definition of disease and the criteria for a disease claim. eCFR, up to date as of October 23, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-F/section-101.93
  17. 21 CFR 190.6, requirement for premarket notification of a new dietary ingredient. eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-190/subpart-B/section-190.6
  18. 21 CFR Part 111, current good manufacturing practice for dietary supplements (§§ 111.1, 111.75). eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111
  19. 21 CFR Part 117, current good manufacturing practice, hazard analysis and risk-based preventive controls for human food (§ 117.5(e)). eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-117
  20. 21 CFR Part 1, Subpart L, foreign supplier verification programs for food importers (§ 1.511 for dietary supplements). eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-1/subpart-L
  21. 21 CFR Part 170, food additives: § 170.30 (GRAS eligibility) and Subpart E, §§ 170.203–170.285 (GRAS notification). eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-170
  22. 21 CFR 170.3(i), definition of safe or safety for food additives. eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-170/subpart-A/section-170.3
  23. 21 CFR Part 171, food additive petitions, § 171.1. eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-171
  24. 21 CFR 312.20 (requirement for an IND), 312.23(a) (IND content) and 312.40(b) (when an IND goes into effect). eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.20
  25. 21 CFR 314.50 (content and format of an NDA) and 314.105 (approval of an NDA). eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.50
  26. 21 CFR 314.126, adequate and well-controlled studies. eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.126
  27. 21 CFR Parts 210 and 211, current good manufacturing practice for drugs and finished pharmaceuticals. eCFR, current to October 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
  28. Federal Register. Substances Generally Recognized as Safe; proposed rule. 91 FR 51834–51881, Aug 11, 2026 (FR Doc. 2026-16296; docket FDA-2025-N-3262). Comments due Dec 9, 2026. federalregister.gov/documents/2026/08/11/2026-16296/substances-generally-recognized-as-safe
  29. New York General Business Law § 391-oo, sale of over-the-counter diet pills and dietary supplements for weight loss or muscle building (revision April 26, 2024). nysenate.gov/legislation/laws/GBS/391-OO

supplement or medicine, FDA and FTC guidance and agency pages

  1. U.S. FDA. NDI Notifications and Related Issues; Identity and Safety Information About the NDI. Final guidance, October 2026 (docket FDA-2025-D-6501), Sections II, IV–IX and Appendix A. fda.gov/media/195770/download
  2. U.S. FDA. Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (revised draft, August 2016; October 2026 revision with Document History), Sections IV.A–IV.D. Docket FDA-2011-D-0376. Draft, not for implementation. fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues
  3. U.S. FDA. Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes. Final guidance, March 2024; docket FDA-2023-D-5280. fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements
  4. U.S. FDA. Botanical Drug Development: Guidance for Industry. December 2016 (Sections II, III, III.A, III.B, V.B, V.C, V.E, VI.C.1, VI.F.1, VII.F). fda.gov/media/93113/download
  5. U.S. FDA CDER. What is a Botanical Drug? Content current as of September 3, 2026; read November 1, 2026. fda.gov/about-fda/cder-offices-and-divisions/what-botanical-drug
  6. Park JK, Lee D, Rui L, Gao X, Furness MS, Wu C. Analysis of Regulatory Botanical Submission Profile for Cancer Management from the U.S. FDA Perspectives. Ther Innov Regul Sci 2025;59:1129–1137 (approval years of the four botanical drugs). pmc.ncbi.nlm.nih.gov/articles/PMC12446141/
  7. U.S. FDA. Investigational New Drug Applications (INDs): Determining Whether Human Research Studies Can Be Conducted Without an IND. Final guidance, September 2013. fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-inds-determining-whether-human-research-studies-can-be
  8. ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Step 4, November 10, 2000). database.ich.org/sites/default/files/Q7%20Guideline.pdf
  9. U.S. FDA. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), Q9–Q11. Content current as of July 16, 2024; read November 1, 2026. fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
  10. U.S. FDA, Human Foods Program. Response to citizen petition on β-nicotinamide mononucleotide (NMN), docket FDA-2023-P-0872 (document FDA-2023-P-0872-2754), September 2025. downloads.regulations.gov/FDA-2023-P-0872-2754/attachment_1.pdf
  11. U.S. FDA. Label Claims for Conventional Foods and Dietary Supplements. Content current as of March 28, 2024; read November 1, 2026. fda.gov/food/nutrition-food-labeling-and-critical-foods/label-claims-conventional-foods-and-dietary-supplements
  12. U.S. FDA. Qualified Health Claims: Letters of Enforcement Discretion (cranberry products, July 21, 2020). Content current as of March 28, 2024. fda.gov/food/nutrition-food-labeling-and-critical-foods/qualified-health-claims-letters-enforcement-discretion
  13. U.S. FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Content current as of September 11, 2024. fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  14. U.S. FDA. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated. Content current as of November 18, 2025. fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  15. U.S. FDA. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Content current as of August 10, 2026. fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
  16. U.S. FDA. Guidance for Industry: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. June 2014. fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology
  17. Federal Trade Commission. Health Products Compliance Guidance (December 20, 2022), Sections I, II.A, III.A.1, III.B, III.B.2 and III.B.5; read November 1, 2026. ftc.gov/business-guidance/resources/health-products-compliance-guidance
  18. EFSA ANS Panel. Scientific opinion on the safety of green tea catechins. EFSA Journal 2018;16(4):5239. doi.org/10.2903/j.efsa.2018.5239
  19. Mueller SC et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006;62:29–36. PMID 16341856. pubmed.ncbi.nlm.nih.gov/16341856/

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]